Physician profile
Paul Dellaquila
NPI 1275594707
$3,220.82
in general payments reported to CMS, 2019-2025
25 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $329 · 2021: $1,003 · 2022: $667 · 2023: $118 · 2024: $303 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,225.69 | 2019-2022 | |
| Novo Nordisk INC | $592.38 | 2019-2023 | Rybelsus, Ozempic |
| Revance Therapeutics, INC. | $309.01 | 2024-2025 | Daxxify |
| Abbvie INC. | $223.97 | 2020-2025 | Botox |
| Astrazeneca Pharmaceuticals Lp | $158.33 | 2019-2022 | |
| Lilly USA, LLC | $119.48 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $69.44 | 2019-2022 | |
| Pfizer INC. | $61.55 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.40 | 2021 | |
| Amarin Pharma, INC. | $57.42 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $55.26 | 2019-2022 | |
| Therapeuticsmd, INC. | $45.31 | 2019 | |
| Glaxosmithkline, LLC. | $43.54 | 2020-2021 | |
| Eisai INC. | $30.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.85 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $15.51 | 2020 | |
| Clarus Therapeutics INC. | $15.00 | 2021 | |
| Antares Pharma, INC. | $15.00 | 2019 | |
| Dexcom, INC. | $15.00 | 2022 | |
| Galderma Laboratories, L.P. | $14.31 | 2025 | |
| Amgen INC. | $14.30 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.64 | 2021 | |
| Althera Pharmaceuticals LLC | $13.19 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.77 | 2019 | |
| Alfasigma USA, INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dellaquila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.